Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for …
Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for … Preliminary data from the Phase 1 trial are expected first half 2021 Additional €3.4 million in non-dilutive funding from SPW-Recherche of the Walloon Region to support advancement of CYAD-211 MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2020 (GLOBE NEWSWIRE) — Celyad Oncology […]
Read More